SCHEMBL1687392

SCHEMBL1687392

COc1ccc(C=Cc2cccc(Cl)c2)c(C(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RELA Q04206 2/20 0.59
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
KMT2A Q03164 2/20 0.55
HPGD P15428 1/20 0.55
GFER P55789 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
AKR1C3 P42330 1/20 0.54
AKR1C2 P52895 1/20 0.54
NFE2L2 Q16236 3/20 0.50
CYP1A2 P05177 3/20 0.50
CYP1A1 P04798 2/20 0.50
CYP1B1 Q16678 2/20 0.50
APP P05067 1/20 0.47
CYP19A1 P11511 1/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP2C9 P11712 1/20 0.46
GRIK1 P39086 1/20 0.46
FADS1 O60427 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1687390 1.00 RELA (0.59) RELAMEN1LMNAKMT2AHPGD
SCHEMBL2685486 0.90 RELA (0.59) RELAMEN1LMNAKMT2AHPGD
SCHEMBL2316051 0.90 RELA (0.59) RELAMEN1LMNAKMT2AHPGD
SCHEMBL1687354 0.89 RELA (0.58) RELAMEN1LMNAKMT2AHPGD
SCHEMBL1687353 0.89 RELA (0.58) RELAMEN1LMNAKMT2AHPGD
SCHEMBL4143068 0.83 CYP1A2 (0.49) RELAMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL26125660 0.81 TTR (0.56) AKR1C3AKR1C2CYP1A2APPCYP2C9
SCHEMBL26125665 0.81 TTR (0.56) AKR1C3AKR1C2CYP1A2APPCYP2C9
SCHEMBL4403012 0.81 NFE2L2 (0.65) MEN1LMNAKMT2AAKR1C3AKR1C2
SCHEMBL2686075 0.81 NFE2L2 (0.65) MEN1LMNAKMT2AAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633312-B2 Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds C-A-I-R BIOSCIENCES GMBH (DE) 2014-01-21 US disclosed
US-20120115862-A1 DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS C-A-I-R BIOSCIENCES GMBH (DE) 2012-05-10 US disclosed
EP-2066640-B1 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES ORGANON NV (NL) 2011-09-07 EP disclosed
US-7906504-B2 N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators N.V. ORGANON (NL) 2011-03-15 US disclosed
EP-2066640-A2 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES N.V. Organon (NL) 2009-06-10 EP disclosed
WO-2008033757-A2 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-20 WO disclosed
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115862-A1 DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS IL1B, NFKBIA, IL1R1 RELA 15/4885MEN1 3031/4885LMNA 4216/4885
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES SULT2A1, ACAT2, HDAC6 RELA 292/4885MEN1 3782/4885LMNA 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.